“Stromal cells in prostate cancer pathobiology: friends or foes?”

被引:0
|
作者
Filippo Pederzoli
Massimiliano Raffo
Hubert Pakula
Francesco Ravera
Pier Vitale Nuzzo
Massimo Loda
机构
[1] Weill Cornell Medicine,Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital
[2] Vita-Salute San Raffaele University,Department of Internal Medicine
[3] Università Degli Studi di Genova,Meyer Cancer Center
[4] Weill Cornell Medicine,undefined
来源
British Journal of Cancer | 2023年 / 128卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The genomic, epigenetic and metabolic determinants of prostate cancer pathobiology have been extensively studied in epithelial cancer cells. However, malignant cells constantly interact with the surrounding environment—the so-called tumour microenvironment (TME)—which may influence tumour cells to proliferate and invade or to starve and die. In that regard, stromal cells—including fibroblasts, smooth muscle cells and vasculature-associated cells—constitute an essential fraction of the prostate cancer TME. However, they have been largely overlooked compared to other cell types (i.e. immune cells). Indeed, their importance in prostate physiology starts at organogenesis, as the soon-to-be prostate stroma determines embryonal epithelial cells to commit toward prostatic differentiation. Later in life, the appearance of a reactive stroma is linked to the malignant transformation of epithelial cells and cancer progression. In this Review, we discuss the main mesenchymal cell populations of the prostate stroma, highlighting their dynamic role in the transition of the healthy prostate epithelium to cancer. A thorough understanding of those populations, their phenotypes and their transcriptional programs may improve our understanding of prostate cancer pathobiology and may help to exploit prostate stroma as a biomarker of patient stratification and as a therapeutic target.
引用
收藏
页码:930 / 939
页数:9
相关论文
共 50 条
  • [41] Regulatory and effector B cells: Friends or foes?
    Matsushita, Takashi
    [J]. JOURNAL OF DERMATOLOGICAL SCIENCE, 2019, 93 (01) : 2 - 7
  • [42] Review of ferroptosis in colorectal cancer: Friends or foes?
    Zheng Wu
    Ze-Xuan Fang
    Yan-Yu Hou
    Bing-Xuan Wu
    Yu Deng
    Hua-Tao Wu
    Jing Liu
    [J]. World Journal of Gastroenterology, 2023, 29 (03) : 469 - 486
  • [43] Review of ferroptosis in colorectal cancer: Friends or foes?
    Wu, Zheng
    Fang, Ze-Xuan
    Hou, Yan-Yu
    Wu, Bing-Xuan
    Deng, Yu
    Wu, Hua-Tao
    Liu, Jing
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2023, 29 (03) : 469 - 486
  • [44] Immune reaction and colorectal cancer:Friends or foes?
    Vincenzo Formica
    Vittore Cereda
    Antonella Nardecchia
    Manfredi Tesauro
    Mario Roselli
    [J]. World Journal of Gastroenterology, 2014, (35) : 12407 - 12419
  • [45] Concomitant medications and circulating tumor cells: friends or foes?
    Di Cosimo, Serena
    Cappelletti, Vera
    [J]. CANCER DRUG RESISTANCE, 2023, 6 (01) : 30 - 34
  • [46] Balloon cells in malformations of cortical development: friends or foes?
    Liu, Zili
    Shen, Xuefeng
    Lin, Kaomin
    Wang, Fengpeng
    Gao, Jin
    Yao, Yi
    Sun, Jianyuan
    [J]. ACTA EPILEPTOLOGICA, 2024, 6 (01):
  • [47] T lymphocyte subsets in cancer immunity: Friends or foes
    Chraa, Dounia
    Naim, Asmaa
    Olive, Daniel
    Badou, Abdallah
    [J]. JOURNAL OF LEUKOCYTE BIOLOGY, 2019, 105 (02) : 243 - 255
  • [48] T cells: Friends and foes in NASH pathogenesis and hepatocarcinogenesis
    Ramadori, Pierluigi
    Kam, Shing
    Heikenwalder, Mathias
    [J]. HEPATOLOGY, 2022, 75 (04) : 1038 - 1049
  • [49] Bystander T Cells: A Balancing Act of Friends and Foes
    Whiteside, Sarah K.
    Snook, Jeremy P.
    Williams, Matthew A.
    Weis, Janis J.
    [J]. TRENDS IN IMMUNOLOGY, 2018, 39 (12) : 1021 - 1035
  • [50] Sphingolipids: Friends or Foes?
    Hayashi, Hiroshi
    [J]. JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2022, 29 (12) : 1696 - 1698